Short answer
Taysha Gene Therapies, Inc. (TSHA) filed its Q3 2026 10-Q quarterly report on Nov 12, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $0 with net income of −$39M.
Q3 2026 key financials · XBRL
- Revenue
- $0
- Net income
- −$39M
- −19.5% YoY · +16.1% QoQ
- EPS (diluted)
- −$0.10
- −11.1% YoY · +16.7% QoQ
Source: XBRL data from the Taysha Gene Therapies, Inc. (TSHA) Q3 2026 10-Q on SEC EDGAR. USD.
Taysha Gene Therapies, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue not disclosed; no product sales, nine-month revenue $0 vs $4.3M YoY
- Operating margin not meaningful; operating loss $41.9M vs $34.0M YoY
- R&D expense $28.8M vs $25.7M, driven by REVEAL and ASPIRE trials
- Cash $422.8M at September 30, 2026; operating cash use $114.2M for nine months
- June 2026 offering generated $215.6M net proceeds; cash runway into second half of 2028
Risk Factors
- No material changes to risk factors disclosed since the December 31, 2025 Form 10-K
- Carried-forward financial risk: adverse events could affect financial condition and results of operations
- Carried-forward market risk: adverse events could reduce the trading price of securities
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Taysha Gene Therapies, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.